You are here: Industry Insights > Yiling Pharmaceutical

News List

Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China prnasia
December 24, 2021
According to Yiling Pharmaceutical's notice on Thursday (UTC+8), the Depression-resolving and Restlessness-relieving Capsules have been approved for marketing via the obtained Drug Registration Certificate...
Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets Granted Drug Certificate prnewswire
September 13, 2021
Yiling Pharmaceutical recently announced that its newly-developed drug Yishen Yangxin Anshen Tablet had been granted official drug certificate by China's National Medical Products Administration (NMPA).
Yiling Pharmaceutical doubled its performance through innovation in 2020 prnasia
April 12, 2021
Yiling Pharmaceutical released its 2020 annual report on Thursday. It achieved an operating revenue of RMB 8.782 billion in 2020, with a year-on-year growth of 50.76%; and net profit attributed to equity holders of RMB 1.219 billion, with a ...
TCM Lianhua Qingwen's Access to Russian Market Marks Its Global Expansion prnasia
November 06, 2020
Yiling Pharmaceutical discloses that it has received the Certificate of Registration for Dietary Supplements approved and issued by the authorized agency of Eurasian Economic Union, which indicates that the company's patent drug Lianhua Qingwen Capsule ..
Sales of Cardio-Cerebrovascular Products and Lianhua Qingwen Surge, Yiling Pharmaceutical Predicting a 50% Increase in Half-year Net Profit prnasia
July 13, 2020
In the evening of July 12, Yiling Pharmaceutical released the performance forecast for the first half year. In the first half of this year, the company achieved a net profit attributable to shareholders of 682 million to 728 million Yuan (USD 97.4 million